We are live on ! Find out more
FULC icon

Fulcrum Therapeutics
FULC

55 hedge funds and large institutions have $163M invested in Fulcrum Therapeutics in 2020 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 18 increasing their positions, 12 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 12

0.45% more ownership

Funds ownership: 74.58% → 75.02% (+0.45%)

10% less funds holding

Funds holding: 61 → 55 (-6)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

43% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 14

56% less capital invested

Capital invested by funds: $374M → $163M (-$210M)

Holders
55
Holders Change
-6
Holders Change %
-9.84%
% of All Funds
1.11%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.04%
New
8
Increased
18
Reduced
12
Closed
14
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$15M
2
RI
RTW Investments
New York
+$13.9M
3
OM
Opaleye Management
Massachusetts
+$5.44M
4
ACP
Acuta Capital Partners
California
+$4.59M
5
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$2.51M

Top Sellers

Rank Fund Capital Flow
1
FCMI
Foresite Capital Management IV
California
-$20.7M
2
EC
EcoR1 Capital
California
-$16.1M
3
PA
Perceptive Advisors
New York
-$15.8M
4
LGM
Logos Global Management
California
-$7.5M
5
MIM
Monashee Investment Management
Massachusetts
-$5.38M
Name Holding Trade Value Shares
Change 		Change in
Stake
TGI
1
TRV GP III
Massachusetts
$47.3M – – –
TGI
2
TRV GP IV
Massachusetts
$18.6M – – –
Fidelity Investments
3
Fidelity Investments
Massachusetts
$14.6M -$172K -14,316 -0.8%
Point72 Asset Management
4
Point72 Asset Management
Connecticut
$12M +$15M +1,249,303 +479%
CC
5
Casdin Capital
New York
$11.4M – – –
RI
6
RTW Investments
New York
$9.12M +$13.9M +1,150,565 New
BC
7
Boxer Capital
California
$5.6M – – –
AI
8
Alphabet Inc
California
$5.38M -$49.4K -4,099 -0.6%
BlackRock
9
BlackRock
New York
$5.23M -$134K -11,155 -2%
Vanguard Group
10
Vanguard Group
Pennsylvania
$4.81M +$2.19M +181,814 +43%
OM
11
Opaleye Management
Massachusetts
$3.58M +$5.44M +452,000 New
HMC
12
Harvard Management Company
Massachusetts
$3.26M – – –
ACP
13
Acuta Capital Partners
California
$3.02M +$4.59M +381,500 New
SB
14
Samsara BioCapital
California
$2.33M – – –
BCM
15
Burrage Capital Management
Massachusetts
$2.31M – – –
Bessemer Group
16
Bessemer Group
New Jersey
$2.27M – – –
State Street
17
State Street
Massachusetts
$1.68M +$59.7K +4,957 +2%
Alyeska Investment Group
18
Alyeska Investment Group
Illinois
$1.66M +$2.51M +208,757 New
Northern Trust
19
Northern Trust
Illinois
$1.41M +$129K +10,696 +6%
Janus Henderson Group
20
Janus Henderson Group
United Kingdom
$1.4M +$2.13M +177,166 New
Geode Capital Management
21
Geode Capital Management
Massachusetts
$1.17M +$264K +21,961 +17%
FT
22
Fiduciary Trust
Massachusetts
$991K – – –
PIM
23
Platinum Investment Management
Australia
$663K – – –
N
24
Nuveen
North Carolina
$397K +$9.56K +794 +2%
Bank of New York Mellon
25
Bank of New York Mellon
New York
$291K +$55.9K +4,641 +15%
1
2 3

FULC Hedge Fund Activity: Q3 2020 in Review

55 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Fulcrum Therapeutics (FULC) for Q3 2020, worth a combined $163M — down 56% from $374M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of FULC and 8 opened new positions — a net loss of 6 holders — while 12 trimmed existing stakes and 18 added.

The largest buyer was Point72 Asset Management, adding an estimated $15M. The largest seller was Foresite Capital Management IV, exiting entirely with an estimated $20.7M sold.

  • 55 institutional investors held Fulcrum Therapeutics (FULC) as of Q3 2020, down from 61 in Q2 2020.
  • Funds reported $163M of Fulcrum Therapeutics stock for Q3 2020, down 56% quarter-over-quarter.
  • 8 funds opened new Fulcrum Therapeutics positions in Q3 2020 and 14 closed out, a net change of -6 holders.
  • The largest Fulcrum Therapeutics buyer in Q3 2020 was Point72 Asset Management, an estimated $15M added.
  • The largest Fulcrum Therapeutics seller in Q3 2020 was Foresite Capital Management IV, an estimated $20.7M sold.

Based on aggregated 13F filings for Q3 2020.